8 active shortage notices across 6 countries · 2 anticipated.
Last updated 24 Sept 2026 · sourced from official medicines regulators
| Country | Severity | Notices | Since | Est. resolution | Source |
|---|---|---|---|---|---|
| Australia | critical | 1 | 8 May 2026 | 1 Dec 2026 | TGA |
| United States | high | 2 | 26 Jan 2024 | — | FDA |
| Colombia |
| high |
| 1 |
| 27 Jul 2023 |
| — |
| INVIMA |
| Canada | medium | 2 | 13 Aug 2024 | 9 Feb 2027 | HC |
| Netherlands | medium | 1 | 10 Mar 2026 | — | CBG-MEB |
| Norway | medium | 1 | 17 Jun 2024 | 31 Dec 2024 | NOMA |
Yes. As of the latest regulator updates, Riluzole has 8 active shortage notices across 6 countries (Australia, United States, Colombia, Canada, Netherlands, Norway). Status is refreshed daily from official regulatory sources.
Regulators attribute the current Riluzole shortages to manufacturing problems, causes not stated by the regulator, supply-chain disruption. The exact cause varies by country and product — each notice on this page links to the official source.
Regulator-estimated resolution dates currently range from 31 Dec 2024 to 9 Feb 2027, depending on country and product. These estimates come from the manufacturers via regulators and often change — check the per-country table above for the latest.
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ regulators across 50+ countries and never publishes unsourced shortage claims.
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.